Ambrisentan reduces pulmonary arterial hypertension but does not stimulate alveolar and vascular development in neonatal rats with hyperoxic lung injury

Ambrisentan, an endothelin receptor type A antagonist, may be a novel therapeutic agent in neonatal chronic lung disease (CLD) by blocking the adverse effects of the vasoconstrictor endothelin-1, especially pulmonary arterial hypertension (PAH)-induced right ventricular hypertrophy (RVH). We determi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Wagenaar, Gerry T. M., Laghmani, El Houari, de Visser, Yvonne P., Sengers, Rozemarijn M. A., Steendijk, Paul, Baelde, Hans J., Walther, Frans J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Physiological Society 2013
Schlagworte:
Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3567362/
https://ncbi.nlm.nih.gov/pubmed/23292811
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1152/ajplung.00073.2012
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge